Excited to have presented today at #EAU26 on “New Therapeutic Options in #BladderCancer". 1/5 Personalised triplets in advanced disease are a major step forward but they're only part of the story ⬇️ @UroDocAsh @OncoAlert @urotoday @EUplatinum @IBCG_BladderCA @Uroweb @JoshMeeks

JUST IN: @US_FDA approves combo HIF2 inhibitor Belzutifan PD1 inhibitor Pembrolizumab in adjuvant Kidney Cancer. Approval based on LS022 trial co-led with @tompowles1 presented @ASCO #GU26 adding another approval to @NobelPrize story with @kaelin_lab @DanaFarber @DanaFarber_GU ! Onward ! Great day for patients ! #HIF2 #oncology #labubu dailynews.ascopubs.org/do/li… blog.dana-farber.org/insight…

🚨 FDA Approves capivasertib Plus Abiraterone as First Targeted Therapy for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer Source AstraZeneca buff.ly/ldFb96p The FDA has approved capivasertib in combination with abiraterone and prednisone as the first targeted therapy for patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive #ProstateCancer . Approval was based on the Phase III CAPItello-281 trial, which demonstrated a 19% reduction in the risk of radiographic progression or death and improved median radiographic progression-free survival by 7.5 months. The decision also highlights the growing importance of biomarker-driven treatment and PTEN testing in advanced prostate cancer. @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin #OncoAlertAF @nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem

Dear Colleagues in #Prostate Cancer Introducing #APCCC26 Live from Lugano🇨🇭with @OncoAlert RT ADT ± ARPI in high-risk localized prostate cancer—where do we stand? Drs. Bertrand Tombal, Christopher Sweeney, and Jeff Michalski discuss patient selection, biomarkers, reimbursement challenges, pelvic nodal RT, and the evidence shaping treatment intensification. in this video: 👇 How should ARPIs be integrated into practice? Series Faculty @BertrandTOMBAL @ChrisSweens1 @jmmrad @drjefstathiou @CaPsurvivorship @LoebStacy @charlesryanmd @AarmstrongDuke @Ecastromarcos @LVM_Walz @piet_ost @Nicola_Fossati @AnthonyMJoshua @Prof_Nick_James @VedangMurthy @AttardLab @Silke_Gillessen @AOmlin Pinging @AmandaNizamMD @scocmem @nataliagandur @gu_onc @tompowles1 @amerseburger @brian_rini @declangmurphy @cdanicas @neerajaiims

CIRCULATE AIO/ABCSG trial ctDNA strongly prognostic: 3-y DFS 52% vs 87%. ITT negative; PP suggests chemo benefit: DFS 77% vs 38%; HR 0.31.

I wrote about where belzutifan fits across the RCC continuum in @OncJournal. Today's adjuvant approval (LITESPARK-022) sits right next to LITESPARK-011 in the post-PD-(L)1 setting, where belzutifan lenvatinib beat cabozantinib on PFS (14.8 vs 10.7 mo, HR 0.70) and ORR (53% vs 40%) and most impactful nearly doubled duration of response. The throughline: earlier HIF-2α targeting may buy durability, but patient selection and careful monitoring of toxicity, and OS immature in both datasets 👉 bit.ly/Beckermann-Belzutifan…

🚨 STAMPEDE: AI biomarker may help select who needs abi intensification in VHR localized #prostatecancer Just out in @Annals_Oncology 🧬 >1k pts w/ non-metastatic very high-risk PCa from 2 randomized STAMPEDE phase 3 abi trials. 🤖 Multimodal AI using routine H&E PSA/stage/age 📉 MMAI very high-risk: abi LT-ADT markedly improved MFS: HR 0.47. 5-yr MFS 81% vs 62%. 🎯 MMAI standard high-risk: benefit was limited: HR 0.83. 5-yr MFS 84% vs 82%. Interaction P=0.02. 🧠 Signal in both node-negative & node-positive pts ⚖️ Implication: intensify where benefit is ⬆️, spare overtreatment/toxicity where benefit is ⬇️. 🔗shorturl.at/FoHKo @PCFnews @PCF_Science @urotoday @UrologyTimes

Dear Colleagues at #ASCO26 Thank you for joining us and reminding you that THE COMPLETE ONCOALERT NEWSLETTER with ALL of our picks from #ASCO26 comes out this Thursday and conveniently to your Inbox REGISTER HERE 👉buff.ly/bTpzTQY @DrChoueiri 🇺🇸 @hoperugo 🇺🇸 @matteolambe 🇮🇹 @TiansterZhang 🇺🇸 @CathyEngMD 🇺🇸 @stolaney1 🇺🇸 @montypal 🇺🇸 @tompowles1 🇬🇧 @brian_rini 🇺🇸 @cdanicas 🇪🇸 @NiuSanford 🇺🇸 @amerseburger 🇩🇪 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @PGrivasMDPhD 🇺🇸 @DrYukselUrun 🇹🇷 @nataliagandur 🇦🇷 @ElisaAgostinett 🇧🇪 @HHorinouchi 🇯🇵 @realbowtiedoc 🇺🇸 @to_be_elizabeth 🇮🇹 @UOzkerim 🇹🇷 @p_ciracimd 🇮🇹 @DrVilmaPBarcia 🇪🇸 @DraMartinezLago 🇪🇸 @DrMirallas 🇺🇸 @GaiaGriguolo 🇮🇹 @MarioBalsaMD 🇪🇸 @scocmem 🇬🇧 @AmandaNizamMD 🇺🇸 & @weoncologists 🇺🇸

How to treat metastatic papillary RCC ? Nice slides from talks by @charlesbnguyen and @ADESAIONCMD @asco #asco26

Top trending women GU cancer oncologists on 𝕏 during @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer | @nataliagandur | @DrKarineTawagi | @katy_beckermann | @AmandaNizamMD | @shilpaonc | @QianJanieQin | @TiansterZhang | @scocmem | @LauraBukavinaMD | @mjuanfi81

Most active cancer institutes in 𝕏 during @ASCO 2026. Ranked by views of oncologist posts on clinical trials. Explore more insights and conference data from #ASCO26 👉 clin.larvol.com/conference/a… #LARVOL #ASCO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #ClinicalOncology #LungCancer #SCLC #esSCLC #NSCLC #LCSM #BreastCancer #TNBC #BCSM #GUCancer #GUCSM #GenitourinaryCancer #KidneyCancer #BladderCancer #ProstateCancer #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #Hematology #Leukemia #Lymphoma #MultipleMyeloma #BloodCancer #HemeOnc #MMSM #LEUSM #LYMSM | @RenovaHospitals | @DanaFarber | @Intermountain | @AnkaraUni | @UTMDAnderson | @juntendo_univ | @NorthwellHealth | @fortis_hospital | @ONealCancerUAB | @Georgetown | @univmiami | @ClevelandClinic | @BCCancer | @UHhospitals | @InstitutoRoffo | @NHSBartsHealth | @UTSWMedCenter | @UIHealth | @DrRishabhOnco | @PTarantinoMD | @DrChoueiri | @marklewismd | @Dave_Gill_SLC | @HHorinouchi | @shimoi_oncology | @AndreaNecchi | @BianchiniGP | @DrYukselUrun | @DrMirallas | @DrBarbiOnc | @Erman_Akkus | @lungoncdoc | @M_Torasawa | @GIMedOnc | @SuyogCancer | @ADesaiMD | @StephenVLiu | @coffman_kelley | @Latinamd | @AmandaNizamMD | @GlopesMd | @dr_yakupergun | @jamecancerdoc | @ronanhsieh | @GillSharlene | @DrSpratticus | @MamMa_mimumemo

New paper just out in @EurUrolOncol - outcomes of patients with intermediate-risk NMIBC when treated with contemporary protocols? We analyzed 578 patients across 4 RCTs. IR NMIBC defined as per @IBCG_BladderCA and 2019 EAU Guidelines - only LG tumors. Real-world relevant data. Here is what we found. 🧵 Ohttps://euoncology.europeanurology.com/article/S2588-9311(26)00127-6/fulltext

ASCO 2026 brought exciting data that will improve outcome for pts globally. Our MIBC organ preservation trial was presented by Nick.I presented cis v Carbo data from DISCUS trial. We saw amazing and exciting data across cancers.Thank you @asco committees for a stimulating meeting

RT @AndreaNecchi: More data on advanced automated use of MRI in #bladdercancer A two-stage foundation model for bladder tumor segmentation:…

Iza-Bren is very effective (not only in TNBC) but its profile is also very chemo-like. What’s the targeted contribution vs non-specific uptake? Iza-Bren half-life is ~1 day! What’s the correlation with EGFR expression? HER3 expression? Co-expression of both EGFR and HER3?

One of my favorite abstracts of this #ASCO26 - reduced denosumab dose intensity (q12w) is NON inferior to q4w in pts with mBC or mCRPC, with improved safety profile in terms of risk of hypocalcemia and osteonecrosis of the jaw Practice changing!! @OncoAlert

🔬 ¡Ya está aquí! El GUARD International Symposium 2026 se celebra los días 16-18 de septiembre en Madrid. Tres días de ciencia, debate y avances en uro-oncología.  🗓️ ¡Consulta el programa preliminar y reserva tu plaza!👇 guardconsortium.org/activida… #guardsymposium2026 @DrFelixGuerrero @cdanicas @dralvaropinto @drenriquegrande @fcounago @docjavip @BerUrologia @DrJaVallejo @Maroto5Pablo @nachoduranm @RodriguezAntona @AnaPlatabello1 @Uro_Oncologist @F_lopez_campos

Congrats to the whole team @DanaFarber_GU on this new @AACR paper in Molecular Cancer Research This is the result of over 4 years of work with 3 labs @DanaFarber, where @adib_elio @AminNassarMD @sarahaboualaiwi were residents/fellows @BrighamMedRes @YaleCancer and @SylvanBacaLab was a post-doc! Thank you @MichelleDunno17 @SashaGusevPosts @mouwlab for being the best collaborators! Link: aacrjournals.org/mcr/article…

Dear Colleagues at #ASCO26 Thank you for joining us and reminding you that THE COMPLETE ONCOALERT NEWSLETTER with ALL of our picks from #ASCO26 comes out this Thursday and conveniently to your Inbox REGISTER HERE 👉buff.ly/Ax3E7T7 @DrChoueiri 🇺🇸 @hoperugo 🇺🇸 @matteolambe 🇮🇹 @TiansterZhang 🇺🇸 @CathyEngMD 🇺🇸 @stolaney1 🇺🇸 @montypal 🇺🇸 @tompowles1 🇬🇧 @brian_rini 🇺🇸 @cdanicas 🇪🇸 @NiuSanford 🇺🇸 @amerseburger 🇩🇪 @GlopesMd 🇺🇸 @Icro_Meattini 🇮🇹 @PGrivasMDPhD 🇺🇸 @DrYukselUrun 🇹🇷 @nataliagandur 🇦🇷 @ElisaAgostinett 🇧🇪 @HHorinouchi 🇯🇵 @realbowtiedoc 🇺🇸 @to_be_elizabeth 🇮🇹 @UOzkerim 🇹🇷 @p_ciracimd 🇮🇹 @DrVilmaPBarcia 🇪🇸 @DraMartinezLago 🇪🇸 @DrMirallas 🇺🇸 @GaiaGriguolo 🇮🇹 @MarioBalsaMD 🇪🇸 @scocmem 🇬🇧 @AmandaNizamMD 🇺🇸 & @weoncologists 🇺🇸

Thanks @OncoAlert for supporting education & making it easy for colleagues, patients, caregivers & advocates to follow key data from @ASCO virtually :-) @fredhutch @HutchPresident @urotoday @RahulBanerjeeMD @VenurVyshak @FaltasLab @HsiehLab @BladderCancerUS @IBCG_BladderCA

Iza-bren is also a promising drug for prostate cancer. Refering to our JCI paper: jci.org/articles/view/201090…